Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature
Sandra J Drozdz, Akash Goel, Matthew W McGarr, et al.
Journal of Pain Research (2022) Vol. Volume 15, pp. 1691-1706
Open Access | Times Cited: 55

Showing 1-25 of 55 citing articles:

Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Kyle A. Brown, Todd D. Gould
Molecular Psychiatry (2024) Vol. 29, Iss. 4, pp. 1114-1127
Open Access | Times Cited: 16
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine
David S. Mathai, Sandeep M. Nayak, David B. Yaden, et al.
Psychopharmacology (2023) Vol. 240, Iss. 4, pp. 827-836
Closed Access | Times Cited: 30
Long term structural and functional neural changes following a single infusion of Ketamine in PTSD
Or Duek, Nachshon Korem, Yutong Li, et al.
Neuropsychopharmacology (2023) Vol. 48, Iss. 11, pp. 1648-1658
Open Access | Times Cited: 23
New and emerging treatments for major depressive disorder
Cecilia Njenga, Parashar Pravin Ramanuj, Frederico Jose Coelho de Magalhães, et al.
BMJ (2024), pp. e073823-e073823
Closed Access | Times Cited: 10
Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism
Jennifer Mitchell, B. Anderson
Neuropsychopharmacology (2023) Vol. 49, Iss. 1, pp. 96-103
Open Access | Times Cited: 21
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Abigail E. Calder, Seline Mock, Nicole Friedli, et al.
European Neuropsychopharmacology (2023) Vol. 75, pp. 1-14
Open Access | Times Cited: 19
Phenomenology and therapeutic potential of patient experiences during oral esketamine treatment for treatment-resistant depression: an interpretative phenomenological study
Joost J. Breeksema, Alistair Niemeijer, Bouwe Kuin, et al.
Psychopharmacology (2023) Vol. 240, Iss. 7, pp. 1547-1560
Open Access | Times Cited: 18
Spiritual health practitioners’ contributions to psychedelic assisted therapy: A qualitative analysis
Caroline Peacock, Jennifer S. Mascaro, Erin Brauer, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0296071-e0296071
Open Access | Times Cited: 6
The therapeutic use and efficacy of ketamine in alcohol use disorder and alcohol withdrawal syndrome: a scoping review
Charlotte Goldfine, Jeremiah J. Tom, Dana D. Im, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 14
Experiences of Awe Mediate Ketamine’s Antidepressant Effects: Findings From a Randomized Controlled Trial in Treatment-Resistant Depression
Julia Aepfelbacher, Benjamin Panny, Rebecca B. Price
Biological Psychiatry Global Open Science (2024) Vol. 4, Iss. 4, pp. 100316-100316
Open Access | Times Cited: 5
The Stress Phenotyping Framework: A multidisciplinary biobehavioral approach for assessing and therapeutically targeting maladaptive stress physiology
Rachel Gilgoff, Summer Mengelkoch, Jorina Elbers, et al.
Stress (2024) Vol. 27, Iss. 1
Open Access | Times Cited: 5
Psychedelics and Psychotherapy: What Can be Learned from a Historical Analysis of General Anesthesia and Surgery?
Christopher S. Stauffer
The American Journal of Bioethics (2025) Vol. 25, Iss. 1, pp. 56-58
Closed Access
Ketamine and Ketamine-Assisted Psychotherapy for Psychiatric and Existential Distress in Patients with Serious Medical Illness: A Narrative Review
Roxanne Sholevar, William Kromka, Yvan Beaussant
Journal of Palliative Medicine (2025)
Closed Access
The ketamine chameleon: history, pharmacology, and the contested value of experience
Danny Diep, Sara de la Salle, Julien Thibault Lévesque, et al.
Expert Review of Clinical Pharmacology (2025)
Closed Access
Chronic Pain and Obsessive–Compulsive Disorder: A Scoping Review
Chad Sloley, Caroline Bell, Edward A. Shipton, et al.
Pain and Therapy (2025)
Open Access
Protocol of an open-label safety and feasibility pilot study of ketamine-assisted psychotherapy for methamphetamine use disorder (the KAPPA trial)
Kathryn Fletcher, Nadine Ezard, Krista J. Siefried, et al.
BMJ Open (2025) Vol. 15, Iss. 2, pp. e092504-e092504
Open Access
Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives
Sung‐Hyun Kim, Sumin Yang, Jeehye Jung, et al.
Advanced Science (2025)
Open Access
Combined ketamine and psychotherapy provide no additional benefit beyond ketamine alone in treating depression or PTSD: Evidence from a help-seeking sample
Tyler M. Moore, Kathryn C. Walker, Elizabeth L. Tung, et al.
Journal of Affective Disorders (2025)
Closed Access
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Courtney M. Vecera, Alan C. Courtes, Gregory Jones, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 11, pp. 1572-1572
Open Access | Times Cited: 12
Exploring the impact of music on response to ketamine/esketamine: A scoping review
Mina Kheirkhah, Allison C. Nugent, Alicia A. Livinski, et al.
Neuroscience & Biobehavioral Reviews (2024) Vol. 162, pp. 105693-105693
Closed Access | Times Cited: 4
Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS
Adelaida Castillo, Julien Dubois, Ryan M. Field, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence
Débora Silva de Oliveira, Rodrigo Fontenele, Jeremy Weleff, et al.
International Review of Psychiatry (2023) Vol. 35, Iss. 5-6, pp. 377-396
Closed Access | Times Cited: 7
Depression with comorbid borderline personality disorder - could ketamine be a treatment catalyst?
Magdalena Więdłocha, Piotr Marcinowicz, Jan Komarnicki, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 2
Ketamine’s Amelioration of Fear Extinction in Adolescent Male Mice Is Associated with the Activation of the Hippocampal Akt-mTOR-GluA1 Pathway
Emilija Glavonic, Milorad Dragić, Miloš Mitić, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 6, pp. 669-669
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top